research The dose‐response of percutaneous oestradiol implants on the skeletons of postmenopausal women
Higher doses of oestradiol implants improve bone density in postmenopausal women.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Wedelolactone, a natural coumestan with multiple pharmacological effects
Wedelolactone may help treat inflammation, infections, cancer, bone loss, and organ damage.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Sorafenib-induced Facial Acneiform Eruption
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes
Ozenoxacin reduces sebum production, helping manage acne.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Latanoprost
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Stimulation of Hair Growth by Topical Application of FK506, a Potent Immunosuppressive Agent
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Heptaminol-Induced Hair Depigmentation in a Hemodialysis Patient
Stopping heptaminol medication reversed hair color loss in a patient on dialysis.
research Minoxidil
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Pathogenesis and management of TRPV3-related Olmsted syndrome
EGFR and mTOR inhibitors may help manage Olmsted syndrome symptoms.
research Alopecia Universalis: Never Give Up?
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Blood Pressure Monitoring for Minoxidil Therapy in Alopecia Patients
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.